ADRB1 and breast carcinoma: β1‐AR antagonists, such as nebivolol, have also been shown to inhibit the growth of colon and breast cancers by suppressing oxidative phosphorylation in cancer cells and preventing endothelial cell proliferation, thereby reducing tumor angiogenesis.31, 327